Rheumatoid Arthritis and Systemic Lupus ErythematosusPhase 1NCT07923747
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
A Phase 1 study testing DKB903 in people with Rheumatoid Arthritis and Systemic Lupus Erythematosus, run by Novartis Pharmaceuticals.
Trial summary
The purpose of this First-In-Human (FIH), Phase 1, open-label, ascending dose study is to determine safety and tolerability of DKB903, in participants with Rheumatoid Arthritis (RA) and participants with Systemic Lupus Erythematosus (SLE) in order to enable further clinical testing in these populations. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Rheumatoid Arthritis and Systemic Lupus Erythematosus
- What is being tested?
- DKB903
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- No sites listed yet
- Study dates
- 1 Dec 2026to 21 Feb 2029
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Signed informed consent must be obtained prior to participation in the study.
- Able to communicate well with the Investigator, to understand the study and willing to comply with the requirements of the study.
- Immunization (primary or from vaccinations) against pneumococcus, influenza and COVID-19 at least 2 weeks prior to the first dosing.
- Male and female individuals, aged 18 to 75 years at screening, diagnosed with RA according to the 2010 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) or 1987 ACR classification at least 12 weeks prior to screening.
- Male and female individuals, aged 18 to 75 years at screening, diagnosed with SLE according to the 2019 ACR/EULAR criteria at least 12 weeks prior to screening.
Who cannot join
- Body weight < 45 kg or > 145 kg and Body Mass Index (BMI) < 16 or > 39.
- Use of prohibited medication or inadequate wash-out as per protocol.
- Protocol-defined cardiac conditions or clinically significant ECG abnormalities or arrhythmia.
- Clinically significant active, opportunistic, chronic or recurrent infection (including Human Immunodeficiency Virus [HIV], Hepatitis B [HBV], Hepatitis C [HBC], and Tubercolosis [TB]) confirmed by clinical evidence, imaging, or positive laboratory tests (e.g., blood cultures, PCR for DNA/RNA) within one month prior to or during screening.
- Serious medical illness likely to interfere with participation in this clinical study.
- Women of childbearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant from menarche until becoming post-menopausal, unless they are using highly effective methods of contraception (failure rate < 1% per year) from the time of enrollment until weeks after last DKB903 administration.
- Other protocol-defined inclusion/exclusion criteria may apply.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
Novartis Pharmaceuticals contact
About this study
Official title: A Two-part, First-In-Human, Phase I, Open-label, Ascending Dose Study to Assess Safety and Tolerability of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
The purpose of this First-In-Human (FIH), Phase 1, open-label, ascending dose study is to determine safety and tolerability of DKB903, in participants with Rheumatoid Arthritis (RA) and participants with Systemic Lupus Erythematosus (SLE) in order to enable further clinical testing in these populations.
Read the detailed description
This is a two-part, FIH, Phase 1, open-label, uncontrolled, ascending dose study designed to evaluate the safety and tolerability of DKB903, in participants with RA and participants with SLE.
- Being tested
- DKB903
- Keywords
- DKB903, ascending dose, Rheumatoid Arthritis, Systemic Lupus Erythematosus.
- Medical subject headings
- Arthritis, Rheumatoid, Lupus Erythematosus, Systemic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DKB903Drug
DKB903
| Study group | Role | What they receive |
|---|---|---|
| Part A- Cohort A-DKB903 | Experimental | Participants will receive DKB903 at escalating dose levels. Receives: Drug: DKB903 |
| Part B- Cohort B-DKB903 dose level identified as safe in Part A | Experimental | DKB903 dose level identified as safe in Part A, plus up to two additional full doses. Receives: Drug: DKB903 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number of participants with AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs.
Measured: From Day 1 up to approximately 2 years.
Secondary outcomes (1)
Presence/absence of anti-drug antibodies (ADA) at baseline and over time
To assess the Immunogenicity (IG) of DKB903
Measured: Baseline, up to approximately 2 years.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2026
- Study start1 Dec 2026 (estimated)
- Primary completion20 Feb 2029 (estimated)
- Study completion21 Feb 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Rheumatoid Arthritis and Systemic Lupus ErythematosusStudies of the same condition, open and under way.
- More trials run by Novartis PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07923747
- Sponsor's protocol ID
- CDKB903A02101
- Other IDs
- 2026-526247-35-00
- Status last verified
- Nov 2026
- First submitted
- 2 Nov 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Two-part, First-In-Human, Phase I, Open-label, Ascending Dose Study to Assess Safety and Tolerability of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
- ClinicalTrials.gov ID
- NCT07923747
- Acronym / sponsor ID
- CDKB903A02101
- Keywords
- DKB903, ascending dose, Rheumatoid Arthritis, Systemic Lupus Erythematosus.
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- Novartis PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- 1 Dec 2026 (estimated)
- Primary completion
- 20 Feb 2029 (estimated)
- Study completion
- 21 Feb 2029 (estimated)
- First posted
- 6 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this First-In-Human (FIH), Phase 1, open-label, ascending dose study is to determine safety and tolerability of DKB903, in participants with Rheumatoid Arthritis (RA) and participants with Systemic Lupus Erythematosus (SLE) in order to enable further clinical testing in these populations.
Detailed description
This is a two-part, FIH, Phase 1, open-label, uncontrolled, ascending dose study designed to evaluate the safety and tolerability of DKB903, in participants with RA and participants with SLE.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Part A- Cohort A-DKB903 | Experimental | Drug: DKB903Participants will receive DKB903 at escalating dose levels. |
| Part B- Cohort B-DKB903 dose level identified as safe in Part A | Experimental | Drug: DKB903DKB903 dose level identified as safe in Part A, plus up to two additional full doses. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Signed informed consent must be obtained prior to participation in the study.
- Able to communicate well with the Investigator, to understand the study and willing to comply with the requirements of the study.
- Immunization (primary or from vaccinations) against pneumococcus, influenza and COVID-19 at least 2 weeks prior to the first dosing.
- Male and female individuals, aged 18 to 75 years at screening, diagnosed with RA according to the 2010 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) or 1987 ACR classification at least 12 weeks prior to screening.
- Male and female individuals, aged 18 to 75 years at screening, diagnosed with SLE according to the 2019 ACR/EULAR criteria at least 12 weeks prior to screening.
Key exclusion criteria (7 listed)
- Body weight < 45 kg or > 145 kg and Body Mass Index (BMI) < 16 or > 39.
- Use of prohibited medication or inadequate wash-out as per protocol.
- Protocol-defined cardiac conditions or clinically significant ECG abnormalities or arrhythmia.
- Clinically significant active, opportunistic, chronic or recurrent infection (including Human Immunodeficiency Virus [HIV], Hepatitis B [HBV], Hepatitis C [HBC], and Tubercolosis [TB]) confirmed by clinical evidence, imaging, or positive laboratory tests (e.g., blood cultures, PCR for DNA/RNA) within one month prior to or during screening.
- Serious medical illness likely to interfere with participation in this clinical study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DKB903DKB903 | Drug | Part A- Cohort A-DKB903, Part B- Cohort B-DKB903 dose level identified as safe in Part A |
Primary outcome
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Day 1 up to approximately 2 years.
Number of participants with AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs.
1 secondary outcome
Presence/absence of anti-drug antibodies (ADA) at baseline and over time
Time frame: Baseline, up to approximately 2 years.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Rheumatoid Arthritis and Systemic Lupus Erythematosus
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
RecruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
Not yet recruiting
MYTP01 for Immune-Mediated Diseases
IgA Nephropathy, Kidney Transplant Recipients
RecruitingPhase 1
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Not yet recruitingPhase 1
A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases
Systemic Lupus Erythematosus, Rheumatoid Arthritis (RA)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Novartis Pharmaceuticals contact
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing DKB903 in people with Rheumatoid Arthritis and Systemic Lupus Erythematosus, run by Novartis Pharmaceuticals.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Novartis Pharmaceuticals (1-888-669-6682, novartis.email@novartis.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) (time frame: From Day 1 up to approximately 2 years.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.